Mild Cognitive Impairment, Mild Alzheimer's
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560, administered either intravenously or subcutaneously, in both healthy participants and patients with Alzheimer's disease. Side effects and laboratory results will be monitored.
The results of this study are not yet available.
Your participation could last up to 16 weeks and include 11 visits to the study center, including a 4 day clinical research unit (CRU) stay.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Healthy participants must be of non-childbearing potential
Alzheimer's disease (AD) participants must be at least 50 years of age
Alzheimer's disease (AD) participants must have either mild cognitive impairment (MCI) or mild-to-moderate AD and have a positive PET scan
Participants must not have an increased risk of seizures